Valisure is a pioneering technology company at the forefront of addressing a critical gap in the healthcare supply chain through independent quality assurance. Our mission is to revolutionize the broken supply chain by providing a critically missing element: transparency to quality and independent certification through chemical analysis. At a time when transparency and reliability have never been more critical, Valisure addresses a significant unmet need, reshaping the future of the healthcare supply chain. Explore collaboration opportunities with us to advance the quality assurance standard in healthcare.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Tellus sapien sed ullamcorper malesuada nulla a, enim tempus. Eget maecenas tortor elementum non.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Tellus sapien sed ullamcorper malesuada nulla a, enim tempus. Eget maecenas tortor elementum non.
Valisure becomes an ISO/IEC 17025:2017 accredited laboratory.
Valisure renews its original laboratory accreditation to ISO/IEC 17025:2017.
Valisure successfully builds and licenses the first online pharmacy that dispenses chemically-validated medications.
April 2018 - Valisure Wins Pre-Revenue Venture Of The Year In The 2018 Connecticut Entrepreneur Awards.
November 2018 - Valisure Publishes Its First Study Titled, “Rapid And Fast-Release Acetaminophen Gelcaps Dissolve Slower Than Acetaminophen Tablets.”
Valisure files its first two FDA Citizen Petitions and has a global impact.
June 2019 - Valisure Detects DMF Carcinogen In Valsartan (Blood Pressure Drug) And Files Its First Citizen Petition.
September 2019 - Valisure Detects NDMA Carcinogen In Ranitidine (Zantac) And Nizatidine (Axid) And Files Its Second Citizen Petition.
September 2019 - Wired Magazine Names Valisure As One Of Three Companies Fixing The Drug Industry.
November 2019 - U.S. Senator Chris Murphy Honors Valisure With His Office’s Innovator Award.
November 2019 - 40+ Countries Act Upon Valisure’s Study Of Ranitidine’s Fundamental Instability.
Valisure’s independent testing and subsequent discoveries generate a growing impact recognized by government and industry.
January 2020 - Valisure Is Invited To A Joint Press Conference With Congresswoman Rosa DeLauro Reintroducing A Bill To Give FDA Mandatory Recall Authority Over Drugs.
February 2020 - Valisure Speaks At FDA's Duke Margolis Think Tank On Perceptions On Pharmaceutical Quality.
March 2020 - Valisure Detects NDMA Carcinogen In Metformin (Top Diabetes Drug) And Files Its Third Citizen Petition.
March 2020 - Valisure Is The First Company To Be Named By MedPage As A Healthcare Disruptor.
April 2020 - Valisure Speaks At The Virtual Summit On Safe Effective High-Quality Medicines.
April 2020 - Valisure Is A Keynote Speaker At The INTERPHEX Pharmaceutical Technology Conference.
June 2020 - David Light Testifies Before The US Senate Finance Committee On FDA Inspections.
September 2020 - Valisure Participates In A Pharmaceutical Shortages & Quality Certification Program.
September 2020 - Valisure Invited By JustMedicine To Participate In A Pharmaceutical Shortages & Quality Certification Program.
December 2020 - GSK Publishes Root Cause Analysis Paper On Ranitidine, Confirming Valisure’s 2019 Theory Of The Drug Reacting With Itself To Form NDMA.
Valisure’s business evolves from direct-to-consumer into enterprise services as impact grows both in drug and consumer products.
March 2021 - Valisure Detects Benzene Carcinogen In Hand Sanitizers And Files Its Fourth Citizen Petition.
May 2021 - Valisure Sells Its Pharmacy Business To Medly Pharmacy And Announces Partnership To Expand Distribution Of Certified Drugs.
May 2021 - Valisure Detects Benzene Carcinogen In Sunscreens And Files Its Fifth Citizen Petition.
May 2021 - Valisure And GOJO Industries Inc. (Makers Of Purell) File Joint Letter To FDA Presenting New Research And Requesting Withdrawal Of Emergency Policy.
June 2021 - Invited Presenter By Agilent Technologies On Benzene Contamination.
September 2021 - Valisure Speaks At CHPA (Consumer Healthcare Products Association) Regulatory Science And Quality Conference.
October 2021 - Valisure Speaks At The Industry Studies Association Pharmaceutical Supply Chain Conference.
October 2021 - FDA Grants Valisure's And GOJO Industries Inc.'s (Makers Of Purell) Requests And Withdraws Emergency Hand Sanitizer Policy.
November 2021 - Valisure Detects Benzene Carcinogen In Body Sprays And Files Its Sixth Citizen Petition.
December 2021 - FDA Requests The Industry Starts Testing For Benzene And Identify Potential Sources Of Contamination Previously Suggested By Valisure.
Valisure’s enterprise business successfully integrates independent quality assurance into major, national health systems and continues to build engagement throughout healthcare.
January 2022 - Valisure Featured On The Cover And Co-Authored A Study Published In Raman Spectroscopy Titled, Raman Spectroscopy Detects Adulterated Counter-Ions In Pharmaceuticals.
March 2022 - Valisure Featured In The Milken Institute Review Titled, Fixing Generic Drugs With Voluntary Privatized Regulation.
March 2022 - Valisure And GOJO Industries (Makers Of Purell) Published A Joint Study Titled, The Presence Of Unsafe Chemical Impurities Accelerated Evaporation Of Alcohol, And Lack Of Crucial Labeling Requirements Are Risks And Concerns For Some Alcohol-Based Hand Sanitizers And Dispenser Practices During The Covid-19 Pandemic,
March 2022 - Valisure’s Analysis of Benzene In Sunscreens, Including Crowdsourcing Samples, Was Published In A Top Academic Journal Titled, Independent Sun Care Product Screening For Benzene Contamination.
April 2022 - Valisure Co-Authored A Study Published In Circulation Titled, Price And Quality In The Generic Pharmaceutical Market.
April 2022 - David Light, Valisure's Ceo, Was Awarded By Junior Achievement The Entrepreneur Of The Year Award.
July 2022 - Valisure’s Participated In A Global Webinar On Benzene Detection In Consumer Products.
October 2022 - Valisure Joins End Drug Shortages Alliance.
October 2022 - Valisure Co-Author In The Journal Of The American Pharmacists Association Paper Titled, A Data-Driven Quality-Score System For Rating Drug Products And Its Implications For The Health Care Industry.
November 2022 - Valisure Announced Its Detection Of Benzene In Dry Shampoo Products.
November 2022 - Valisure Featured In Bloomberg’s The Big Take Column Titled, A Tiny Lab Finds Danger On Drugstore Shelves While The Fda Lags Behind.
November 2022 - Congresswoman Dingell And Congresswoman Stevens Wrote A Joint Letter To FDA Highlighting Valisure’s Citizen Petitions On Benzene Contamination And Requesting Action.
Valisure further expands its enterprise footprint with strong US government engagement and partnerships, in addition to expanding services in private healthcare systems.
January 2023: GOJO and Valisure are collaborating to accelerate independent quality assurance and help ensure that only safe and effective hand hygiene products are available in public settings.
March 2023: Congresswoman Rosa DeLauro wrote to FDA Commissioner Robert Califf questioning whether the agency plans to investigate GSK’s actions regarding Zantac.
April 2023: With drug shortages reaching record levels in the US and quality problems being a leading cause, Bloomberg reported that the White House has engaged experts, including Valisure, to help develop solutions.
April 2023: Valisure's CEO, David Light, was invited to speak at the Stanford Medicine Grand Rounds and present the topic, "Drug Quality & Safety Issues in the US and Strategies to Address Them."
June 2023: Kaiser Permanente, one of the largest healthcare delivery systems in the U.S., spoke publicly about our partnership of 2 years on additional drug quality checks.
June 2023: Valisure’s CEO, David Light, spoke at Bluesight’s Medication Intelligence Summit titled “Proposing a Quality-Score System to Address Drug Quality in the United States.”
June 2023: Valisure’s CEO, David Light presented at the 71st ASMS Conference on Mass Spectrometry & Allied Topics on "Real-Time Measurement Of Benzene In Aerosol Consumer Products Using SIFT-MS."
August 2023: Valisure entered into a Cooperative Research and Development Agreement with the Department of Defense in order to generate objective drug quality data through independent chemical testing of certain drugs.
August 2023: US Army Colonel, Victor Suarez and David Light, co-presented a learning lab session at The Association for Healthcare Resource & Materials Management (AHRMM) Annual Conference. Their AHRMM paper, titled "Drug Shortage, Safety, Quality & Effectiveness Crisis: A Quadruple Threat to Healthcare & National Security," delves into the intricate background and landscape contributing to the prevailing drug shortages in the US.
August 2023: Invited on behalf of Syft Technologies, Valisure’s CEO, David Light, was featured on the on-demand webinar entitled, "Quantitative Impurities Analysis of Consumer Products using SIFT-MS."
August 2023: Bloomberg commissioned Valisure to investigate global cough syrup contamination and Valisure was credited for testing and identifying ethylene glycol in cold medications. Bloomberg shared the test results with the World Health Organization (WHO), in which WHO told Bloomberg that it found Valisure’s test results to be “acceptable” and that it would issue an alert. International recalls also followed.
October 2023: A Metformin paper published in The American Journal of Managed Care (AJMC) titled, Safety vs Price in the Generic Drug Market: Metformin, co-authored by researchers at Valisure and Stanford University.
December 2023: Valisure’s engagement with the DoD expands to include an official project at the Uniformed Services University.
December 2023: In new guidance, the FDA urged manufacturers to reformulate various drug products containing “carbomer” gelling agents, which, as Valisure’s Petition pointed out, pose a high risk of benzene contamination. This guidance targets creams, gels, lotions, ointments, tablets, capsules, and oral suspensions.
Valisure sees the gap of independent testing as an opportunity, and the journey has been very personal. Founders Adam Clark-Joseph and David Light, friends since their Yale days, reconnected after Adam suffered severe complications from his anticonvulsant medication due to batch variability. Shocked by the vulnerability of the existing drug supply chain, they began to grasp the magnitude and pervasiveness of the problem throughout the pharmaceutical industry. Working together to bring a team of like-minded scientists and pharmacy experts to create Valisure, they founded a company dedicated to bringing improvements in quality and consistency to consumers and the overall healthcare industry.
Learn MoreValisure was founded and funded by a team of Yale entrepreneurs.
Valisure successfully builds and licenses the first online pharmacy that dispenses chemically-validated medications.
Valisure’s independent testing and subsequent discoveries generate a growing impact recognized by government and industry.
Valisure’s enterprise business successfully integrates independent quality assurance into major, national health systems and continues to build engagement throughout healthcare.
Valisure achieves laboratory accreditation to ISO/IEC 17025:2017.
Valisure broadly launches pharmacy and files its first two FDA Citizen Petitions creating global impact.
Valisure further expands its enterprise footprint with strong US government engagement and partnerships, in addition to expanding services in private healthcare systems.
Valisure’s business evolves from direct-to-consumer into enterprise services as impact grows both in drug and consumer products.
